Tirzepatide, also known as LY3298176, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for research in type 2 diabetes treatment. It demonstrates superior efficacy in glucose control and weight loss compared to other agonists like Dulaglutide.
With a greater affinity for GIP receptors, Tirzepatide mimics natural GIP actions, contributing to significant hyperglycemia reduction. Its molecular structure includes a PEG-modified lys side chain, enhancing water solubility and functionality for research applications.
Clinical studies, such as the SURMOUNT-1 trial, have shown that Tirzepatide can lead to substantial weight loss in overweight subjects, with average reductions of 15% to 20.9% over 72 weeks depending on dosage. It has received FDA Fast Track designation for obesity-related research, highlighting its potential in metabolic studies.
This product is supplied as a white lyophilized powder with high purity, ensuring reliability for laboratory use. It is intended for research purposes only and not for personal consumption.